Medicus Pharma Ltd. (MDCX)

CIK 0001997296 · Healthcare · Drug Manufacturers

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest Q1-2026 —
FY-2025
Latest FY-2025 —
Q3-2025 —
Q2-2025 —
Q1-2025 —
FY-2024
FY-2024 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
Statements
Consolidated Balance Sheets
Unaudited Condensed Consolidated Balance Sheets
—
Consolidated Balance Sheets (P)
Unaudited Condensed Consolidated Balance Sheets (P)
—
Consolidated Statements of Operations and Comprehensive Loss
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
—
Condensed Consolidated Statements of Changes In Shareholders' (deficit) Equity (unaudited)
—
Condensed Consolidated Statements of Changes In Shareholders' Equity (deficit) (unaudited)
—
Consolidated Statements of Changes In Shareholders' Equity
—
Unaudited Condensed Consolidated Statements of Changes In Shareholders' Equity
—
Condensed Consolidated Statements of Changes In Shareholders' (deficit) Equity (unaudited) (P)
—
Condensed Consolidated Statements of Changes In Shareholders' Equity (deficit) (unaudited)(P)
—
Consolidated Statements of Changes In Shareholders' Equity (P)
—
Unaudited Condensed Consolidated Statements of Changes In Shareholders' Equity (P)
—
Consolidated Statements of Cash Flows
Unaudited Condensed Consolidated Statements of Cash Flows
—
Notes
Antev Agreement
—
Antev Asset Acquisition
Balance Sheet Components
Commitment and Contingencies
Cybersecurity Risk Management and Strategy Disclosure
—
Debentures
Description of Business
Fair Value Measurements
Income Taxes
—
Insider Trading Arrangements
—
Leases
Liquidity
—
Liquidity and Going Concern
—
Net Loss Per Share
Pay Vs Performance Disclosure
—
Related Party Transactions
Reverse Takeover Transaction
—
Segment Reporting
Share Capital
Stock-based Compensation
Subsequent Events
Summary of Significant Accounting Policies